Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients |
| Type de publication | Journal Article |
| Year of Publication | 2016 |
| Auteurs | Allavena C, Katlama C, Cotte L, Roger PMarie, Delobel P, Cheret A, Duvivier C, Poizot-Martin I, Hoen B, Cabie A, Cheret A, Lahoulou R, Raffi F, Pugliese P, Grp D'AIDSstudy |
| Journal | INFECTIOUS DISEASES |
| Volume | 48 |
| Pagination | 392-398 |
| Date Published | MAY 3 |
| Type of Article | Article |
| ISSN | 2374-4235 |
| Mots-clés | etravirine, HIV, NNRTI, Tolerability, virological efficacy |
| Résumé | {Objectives Etravirine (ETR) was approved in France in September 2008 and is used in combination with a boosted protease inhibitor (bPI) and other anti-retrovirals (ART) in HIV-infected pre-treated patients. This study aimed to report in a real-life setting the efficacy and tolerability of ETR-based regimens and factors associated with virological response. Methods The study population included all treatment-experienced patients who initiated an ETR-based regimen between September 2008 and July 2013 from the French Dat'AIDS cohort. Analyses were performed in ART-experienced patients starting ETR after virological failure (VF) or as a maintenance therapy (MT), with or without bPI. Results A total of 2006 patients (VF |
| DOI | 10.3109/23744235.2015.1133927 |